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ontinuous
T-Segment Monitoring
n Contemporary Acute
oronary Syndrome Patients
he Magic of MERLIN–TIMI 36*
an Tzivoni, MD,† Mitchell W. Krucoff, MD‡
erusalem, Israel; and Durham, North Carolina
cute coronary syndrome (ACS) is characterized by re-
eated transient ischemic episodes (TIE), which can be
ymptomatic or silent. The frequency of TIE reported in
atients with ACS varies from 15% to 77% across studies,
ue to variations in inclusion/exclusion criteria, modalities
f therapy, monitoring period and number of leads used for
ontinuous electrocardiographic (cECG) monitoring (1,2).
lootwijk et al. (2) detected ischemic changes in 77%
See page 1411
f 130 patients with unstable angina pectoris (UAP) using
2-lead cECG monitoring for 48 h. In the ESSENCE
Efficacy and Safety of Subcutaneous Enoxaparin in Non–
-wave Coronary Events) study (3), monitoring 220 pa-
ients with non–ST-segment elevation (NSTE) ACS for
8 h with 3-lead Holter, Goodman et al. (3) recorded TIE
n 25%. Akkerhuis et al. (4), who obtained data from the
APTURE (C7E3 Fab Anti Platelet Therapy in Unstable
efractory Angina), the PURSUIT (Platelet Glycoprotein
Ib/IIIa in Unstable Angina: Receptor Suppression Using
ntegrilin Therapy), and the FROST (French Randomized
ptimal Stenting Trial) studies in patients with NSTE
CS found ischemic episodes in 27% of 995 patients who
ad 24-h cECG monitoring. Langer et al. (5) reported
schemic changes in 66% of 135 patients with UAP.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Cardiology Department, Shaare Zedek Medical Center, Jerusalem,
srael; and the ‡Duke University Medical Center, Duke Clinical Research Institute,
urham, North Carolina. Dr. Krucoff has received research grants and consulting feesm
rom Philips Medical, GE Medical, Mortara Instrument, Heartscope, NorthEast
onitoring, and NewCardio.echanism
schemia on cECG has been described in association with
oth severe and high risk morphology coronary anatomy in
CS patients. Bugiardini et al. (6) described prolonged
60 min) duration of myocardial ischemia on Holter
onitoring of patients with complex coronary disease, and
ozzati et al. (7) reported both prolonged duration (85 vs.
3 min) and more frequent TIE (56% vs. 9%) in such
atients compared to patients with smooth, less complex
esions. Like Scirica et al. (8) and the TIMI 36 (Throm-
olysis In Myocardial Infarction 36) group, who in this issue
f the Journal report an increased incidence of ischemia in
atients with greater extent of coronary disease (12.3% of
atients with single-vessel disease, 18.9% with double-vessel
isease, and 28.0% with triple-vessel disease), Patel et al. (9)
ound that the dichotomous presence or absence of TIE was
very powerful predictor of complex coronary lesion or
oronary thrombus (odds ratio: 7.1), whereas Langer et al.
5) reported more left main and severe multivessel disease in
atients with TIE.
Patients with ACS have impaired endothelial function
ith increased tendency for coronary vasoconstriction
10,11). Scirica et al. (8) document ST-segment shifts in
10% of patients without flow-limiting coronary lesions, as
ell as in patients after complete revascularization with
ercutaneous coronary intervention. The combination of
ore complex and more advanced coronary pathology as
ell as increased coronary tone may provide further mech-
nistic insight into how strongly TIE relate to impaired
rognosis even in the most modern setting of medical and
ercutaneous coronary intervention therapy.
rognosis
tudies involving patients with NSTE ACS have consis-
ently demonstrated that the presence of TIE is predictive of
oth short and long-term increase in mortality and infarc-
ion. Gottlieb et al. (12) were the first to demonstrate that
IE (mostly silent), which were present in 37 of 70 patients
ith UAP under best medical treatment, were the best
redictors of early cardiac events among 15 tested variables.
imilarly, in the 135 patients with UAP mentioned above,
anger et al. (5) found a higher frequency of cardiac events
48% vs. 20%) among patients with TIE than among patients
ithout TIE. In the meta-analysis from the CAPTURE,
URSUIT, and FROST studies, Akkerhuis et al. (4) found
eath and myocardial infarct in 5.7% of patients without
schemic episodes, compared with 19.7% of patients who
ad 5 episodes. In the ESSENCE trial, Goodman et al.
3) reported death or myocardial infarction at 1 year in
8.4% of patients with TIE and in 8.3% of patients without
IE. Yan et al. (13) investigated the additional prognostic
nformation of 48-h cECG monitoring in 681 NSTE ACS
atients. Over 30 months, patients with ST-segment shifts had
higher risk of death (17.7% vs. 5.9%) or death and
yocardial infarction (24.6% vs. 11.1%). In multivariate
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April 21, 2009:1422–4 Prognostic Value of Ischemic Episodes in ACSnalysis adjusting for the GRACE (Global Registry of
cute Coronary Events) risk score, the presence of ST-
egment shifts remained an independent predictor of death
hazard ratio: 2.37, p  0.002) and death/myocardial
nfarction (hazard ratio: 1.93, p  0.003).
Scirica et al. (8) report their experience from the
ERLIN–TIMI 36 (Metabolic Efficiency With Ranolazine
or Less Ischemia in Non–ST-Elevation Acute Coronary
yndrome–Thrombolysis In Myocardial Infarction 36) trial of
,355 patients undergoing an average of 6 days of uninter-
upted 2-lead Holter monitoring of patients presenting with
CS randomly assigned to treatment with Ranolazine or
lacebo, stratified by conservative versus early invasive strate-
ies. In this landmark study, the authors confirm that despite
ll modern advances in therapy, 20% of patients have TIE, and
hese patients have higher mortality and morbidity than do
atients without TIE. The TIE were more commonly present
n patients with a high-risk profile, namely, older patients
age 65 years) with impaired renal function, prior angina
r heart failure, and ischemic changes on ECG at presen-
ation. The TIE also predicted added risk beyond models
sing several clinical and laboratory parameters. In patients
ith TIE, the adjusted hazard ratio for cardiovascular death
as 2.46 (p  0.001). The hazard ratio for cardiovascular
eath with TIE was higher for every subgroup of pa-
ients: 2.7 for patients 65 years of age and 2.3 for
atients 65 years of age, 2.8 for prior angina, 3.2 for
revious myocardial infarction, 2.8 for previous heart
ailure, 2.6 for TIMI risk score of 5 to 7, 3.0 for
reatment with conservative strategies and 2.2 for treat-
ent with early invasive strategy, 3.8 for ejection fraction
40%, 3.0 for positive troponin and 4.7 for negative
roponin, and 4.7 for normal levels of brain natriuretic
eptide and 2.3 for elevated levels. Even in a very low
linical risk population (negative troponin, low level of
rain natriuretic peptide, no ECG changes on admission)
r ejection fraction 40%, the presence of TIE was
ssociated with significantly elevated hazard ratio for
eath of 2.2 to 4.3, compared with similar patients who
ad no TIE.
The presence or absence of symptoms during TIE is not
eported for the MERLIN–TIMI 36 cohort. That repre-
ents a limitation to understanding the potential prognostic
ifferences between silent and symptomatic TIE, with the
ossibility to further risk stratify this patient group.
Unlike many previous studies, continuous variables, such
s the frequency and duration of ischemia, did not carry
rognostic information in the MERLIN–TIMI 36 trial
xperience beyond the dichotomous presence or absence of
IE per se, although there were some suggestive numerical
rends. Furthermore, by performing 6 days of cECG mon-
toring, the authors were able to demonstrate that late
schemic episodes (beyond 72 h) were detected in only 5% of
atients managed with a conservative strategy, and in only
.5% of patients managed with an aggressive strategy.
BThe use of cECG acutely for 24 to 72 h using 12-lead
olter monitoring, followed by exercise testing 5 to 7 days
ater, was not tested in the MERLIN–TIMI 36 trial as an
lternative to a week of 2-lead Holter monitoring. That
ight yield more predictive information, as discussed be-
ow, with less logistical burden. It is widely appreciated that
lmost all patients who have TIE during ambulatory mon-
toring have abnormal exercise tests (14), and by 5 to 7 days,
ost ACS patients are ambulatory and can safely perform
xercise tests.
echnical Aspects of ST-Segment Monitoring for TIE
ignal fidelity, number of leads, lead location, and duration
f monitoring are all key aspects of TIE quantification.
cirica et al. (8) used 2 bipolar leads at a 128-Hz sampling
ate, whereas in other reports, continuous 3-lead vectorcar-
iographs or 12-lead cECG sampling at 500 to 1,000 Hz
as used. This is an important difference because not only is
schemia episodic in time, but also it is focal over the
recordial “space” as well (15). Too few precordial leads may
iss TIE altogether or may underestimate duration or peak
T-segment deviation of TIE (2,16), a potential factor in
hy number of episodes, ischemia duration, and ST-
egment deviation curve area were not predictive of clinical
utcomes in the MERLIN–TIMI 36 report.
onclusions
his study by Scirica et al. (8) is the largest and most
ontemporary report of continuous Holter ST-segment
onitoring of patients with coronary artery disease in the
iterature, and thus provides unique statistical power to
xamine key subgroups of interest. This study strongly
onfirms that TIE and/or ST-segment shift have prognostic
ignificance for ACS patients, patients treated medically
nd/or undergoing percutaneous coronary intervention, pa-
ients with both complete and incomplete revascularization,
nd patients who are otherwise categorized as high or low
isk using contemporary serologic markers and descriptor
odels.
Despite the very clear prognostic value of the information
btained from cECG monitoring and guidelines supporting
his concept, at present it is not yet practical to perform
ontinuous monitoring of all ACS patients for clinical
urposes, as accurate and reliable online automated ischemia
etection systems are not available. Even if and when such
ystems are developed, to go beyond research applications, it
ill be critical to show that cECG-guided therapy actually
an lead to improved outcomes.
eprint requests and correspondence: Dr. Dan Tzivoni, Direc-
or, Cardiology Department, Shaare Zedek Medical Center, P.O.
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